

---

## Moberg Pharma Q4'2023 - Lots of progress in a short time

Redeye sees the end-of-year report as results as uneventful. More important were the indications of a good start to the Swedish launch, the conclusion of the enrollment to the Phase 3 study, and progress regarding the Terbinafine supply. These factors are essential next steps for Moberg Pharma's commercialization of MOB-015. The national approvals in the remaining countries in the DCP process are in process and will be approved.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Moberg Pharma Q4'2023 - Lots of progress in a short time](#)